Thomas B. Cueni
Thomas B. Cueni is Director General of IFPMA (www.ifpma.org), the association representing the research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health. He is also chair of the AMR Industry Alliance (www.amrindustryalliance.org) and Industry Co-Chair APEC Biopharmaceutical Working Group on Ethics.
Prior to joining IFPMA, Cueni was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland whilst being involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA. Thomas Cueni has served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He began his working life as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).
Thomas B. Cueni is Director General of IFPMA (www.ifpma.org), the association representing the research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health. He is also chair of the AMR Industry Alliance (www.amrindustryalliance.org) and Industry Co-Chair APEC Biopharmaceutical Working Group on Ethics.
Prior to joining IFPMA, Cueni was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland whilst being involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA. Thomas Cueni has served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He began his working life as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).
Articles: Thomas B. Cueni
Health at the UN General Assembly: Innovation & Equity for Pandemic Preparedness
Global / Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global leaders must ensure science and innovation can again deliver at record speed and scale while supporting voluntary partnerships and enabling scientists to have unhindered access…
The Power of Partnerships & Innovation: Accelerating Progress Toward Universal Health Coverage by 2030
Global / The UHC2030 Private Sector Constituency (UHC2030 PSC), which is hosted by the World Bank Group, has released a statement on the private sector commitments toward universal health coverage (UHC), ahead of Multi-stakeholder Hearings on UHC that will take place in New York on 9th May 2023. The IFPMA’s Thomas Cueni shares his views on the…
The IFPMA’s Five Pandemic Preparedness & Response Priorities
Global / IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of COVID-19. The international community is working to rebuild the global health architecture to ensure it is fit for purpose to prepare and respond to…
The Biopharmaceutical Industry’s Three Priorities to Urgently Increase COVID-19 Vaccine Access
Global / As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, contributing to equitable distribution, and driving innovation. From the early days of the COVID-19 pandemic, the…
IFPMA’s Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
APAC / Drawing on the findings of a recent report launched under the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some of the key trends that emerged from report, conducted by Ethisphere, and why “in times…
IFPMA’s Thomas Cueni on why “#TeamVaccines is all of us”
Global / Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort. The story of COVID-19 vaccines is one of incredible…
Speeding up the Search for Safe & Effective COVID-19 Therapies & Vaccines
Coronavirus / IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.* Last week, high-level representatives from seven companies – Takeda, Merck, AstraZeneca, CSL…
Thomas Cueni on Pharma’s Role to Support Universal Health Coverage
IFPMA / On Universal Health Coverage day, the Director General of IFPMA (the International Federation of Pharmaceutical Manufacturers and Associations) explains UHC and how the biopharmaceutical industry is part of the solution. Our industry is much more than a supplier of medicines and vaccines and is increasingly pioneering new ways to overcome the multiple barriers to accessing…
Thomas Cueni on pricing and developing markets
Regulation / In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets. The innovative pharmaceutical industry seems to be under unprecedented pressure as drug development costs rise,…
Latest Report
